Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Elsafadi, M
Nat Commun 16 , 3389 (2025)
The study record describes 28 weeks of treatment, including an initial four-week dose-increase period and a 24-week period used to measure the main results
Aescin has demonstrated evidence of its clinically noteworthy efficacy in the therapy of thyroid cancer 34 , liver dysfunction 35 , hyperlipidemia 36 , diabetes 37 , cardiac vein insufficiency, post-operative edema 38 , cardiac damage 39 , brain trauma 40 , and neurobehavioral disorders 41
Another control-HGF group ( light-blue bars 5 , receiving a solvent followed by the wash-out step) also displayed a low activation index comparable to the level of the control HGF ( gray bars 3 ), indicating again that the solvent of LASSS is not involved in the mechanism that elevates c-met binding, as shown in Figure 1e, right column
None of these studies should be interpreted as recommending BPC-157 for human use, treatment, or any clinical purpose
US$ 27.40
US$ 26.00
US$ 29.27
US$ 29.05
